Head and neck squamous cell carcinoma (HNSCC) frequently develops in the oral and upper aerodigestive regions following chronic exposure to mutagenic ...

A hockey broadcaster reveals she underwent surgery after a spot on her nose that she thought was a pimple turned out to be ...

BioNTech's BNT113 misses Phase III PFS endpoint in HPV16-positive head and neck cancer. Read the full trial update and what ...

Researchers at Tokushima University found that combined TP53 and CDKN2A mutations activate cGAS–STING-mediated antitumor ...

A phase 2/3 trial of BioNTech's immunotherapy for head and neck cancer, BNT113, has failed to meet its objective, but the ...

One of BioNTech's prospective cancer vaccines has failed to show benefit in one of its dual primary endpoints in a Phase ...

Head and neck squamous cell carcinoma (HNSCC) frequently develops in the oral and upper aerodigestive regions following ...

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 ...

BioNTech Shares Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy in Metastatic HPV16-Positive HNC / ...

BioNTech shares fell after BNT113 failed its progression-free survival endpoint.Executive insider share sales under ...

INTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results for investigational ...

HPV16-positive HNSCC represents a subset of head and neck cancers, and treatment options remain limited for patients with recurrent or metastatic disease. BNT113 received Fast Track Designation from ...